Shire acquires Pervasis Therapeutics
This article was originally published in Scrip
Shire plc continues to diversify from its addiction to attention deficit hyperactivity disorder (ADHD) drugs by adding to its nascent regenerative medicines business through the acquisition of Pervasis Therapeutics. The acquisition will provide Shire with a new cell-based technology platform plus a Phase II product candidate that will complement its 2011 purchase of Advanced BioHealing. (scripintelligence.com, 18 May, 2011).